Bioengineers from ETH Zurich’s Department of Biosystems Science and Engineering in Basel have created a prototype implantable molecular device which regulates the blood pH levels through a closed loop pH sensing and insulin production mechanism.
We hear all the hype when new diabetes research is announced: Hey, we’re so excited and think it could be the greatest next big thing. That’s the hope, at least. But what happens if and when that research doesn’t bear any fruit? When the money invested doesn’t produce any potential new therapy or actual product?
As part of the study, conducted at the Diabetes Center of the General Hospital of Nikaea in Athens, Greece, researchers served desserts after meals to 70 study participants with type 2 diabetes, and found that those containing sucralose and soluble fiber did not elevate after-meal levels of glucose, insulin or C-peptide, an amino acid associated […]
As you may know, our correspondent Wil Dubois was on the ground in Orlando, FL, covering the big annual American Association of Diabetes Educators (AADE) meeting for us last week. Check out his first Newsflash on Asante and Insulet stuff from last Friday. And now, we bring you his full report of product news from […]
In Part 1 of our interview (published last Thursday), Derek told us about his personal connection to diabetes and how he views the JDRF overall as an organization. Today, he delves more deeply into just where he thinks the nonprofit org is going and what he thinks it takes to move forward.
The objective of the study, published in leading diabetes journal Diabetes, Obesity and Metabolism, was to compare all-cause mortality in diabetic patients treated with either sulphonylurea or metformin with matched individuals without diabetes including age, gender, same general practice, smoking status and clinical status criteria.
After a decade-long run, Novo Nordisk’s FlexPen is being retired. Yes, one of the most popular insulin pens for people with diabetes is on the way out after more than 1 billion have been sold through the years. And here comes Novo’s new next-gen FlexTouch.
Many people believe that insulin causes the complications of diabetes. Here is some information to dispel some of these myths about insulin therapy.
Access to continuous glucose montitors (CGMs) shouldn’t be a battle in 2014, but for those people with diabetes covered by Medicare, that’s sadly the case. Now there’s a movement afoot to do something about that.
It’s official: Tandem Diabetes Care has made its filing with the U.S. FDA for an integrated insulin pump and continuous glucose monitor — a new device that combines their sexy t:slim touchscreen pump with a Dexcom G4 Platinum CGM.
Insulin pumps can be as beneficial for those with type 2 diabetes that require insulin as they have become for those with type 1, according to a new trial. The study results are especially positive since many of those with type 2 are failing to control their blood glucose levels, which can lead to potentially […]
A group of European health regulators have recommended the approval of a drug treatment that combines long-lasting insulin with a drug that promotes insulin secretion. Also in the news: A new study is examining whether a common gout medication can help prevent kidney disease in people with Type 1 diabetes.
Novo Nordisk has introduced the Levemir® FlexTouch® prefilled insulin delivery device to the U.S. market. The device, filled with insulin detemir [rDNA origin], the first of its kind that does not use a pushbutton extension. In a conventional insulin delivery device, a pushbutton extends out from the device.
A new formulation of insulin that is delivered via inhaler promises the elimination of needles for patients with diabetes. So why hasn’t there been more fanfare over the anticipated arrival of Afrezza?
It’s been about three months since we launched the DiabetesMine Test Kitchen, a central hub for people with diabetes to share their experiences TestKitchen_Logo_Final_lg (1)with products created to improve life with this illness. Today, we’ve added another great new review from D-blogger and advocate Melissa Lee.
Should people with diabetes always have access to their diabetes data and be able to react, or is it better at times to “fly blind” and leave the data-based decision-making in the doctor’s hands?
At the recent 74th annual American Diabetes Association Scientific Session in San Francisco, results from a simultaneously published article in the New England Journal of Medicine were formally announced. The publication consisted of two separate studies demonstrating the efficacy and safety of an “artificial” or “bionic” pancreas for people with type 1 diabetes.
Patients in the study all had uncontrolled type 2 diabetes and were between the ages 30 to 75. Results showed that after 6 months, patients with an insulin pump had a significantly greater decrease in their average blood glucose levels compared to the patients who had multiple injections per day.
An agreement between the Google[x] resesearch lab and pharmaceutical giant Novartis will license the technology for actual medical use for people with diabetes and other conditions.
We have two new reviews to share with you. First, we have a review of the new, smaller OmniPod tubeless insulin pump system, by pumper Greg Nickleski. Second, we have a review of Level Foods glucose gels reviewed by Kimberly Hislop.